Vertex Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
VRTX Vertex Pharmaceuticals Inc
HBI HanesBrands Inc
TMKR Tastemaker Acquisition Corp
SPY SPDR® S&P 500 ETF Trust
STOR STORE Capital Corp
PIPP^ Pine Island Acquisition Corp
PEP PepsiCo Inc
$NASI5000LMN NASDAQ Asia Cnsmr Svcs Large Mid Cap
PNM PNM Resources Inc
CBLAQ CBL & Associates Properties Inc
Go

Health Care : Biotechnology | Large Cap Growth
Company profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Closing Price
$211.98
Day's Change
4.19 (2.02%)
Bid
--
Ask
--
B/A Size
--
Day's High
212.60
Day's Low
206.39
Volume
(Light)
Volume:
1,704,848

10-day average volume:
2,342,889
1,704,848

Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Valuation Ratios

Price/Earnings (TTM)
20.57x
Price/Sales (TTM)
8.88x
Price/Book (MRQ)
6.34x
Price/Cash Flow (TTM)
19.53x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

February 2021
Current Month
4.0M
Previous Month
3.5M
Percent of Float
1.54%
Days to Cover
1.5916 Days

Share Information

VRTX is in a share class of common stock
Float
259.4M
Shares Outstanding
260.0M
Institutions Holding Shares
1,372
92.72%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Jeffrey M. LeidenChmn.
  • Reshma KewalramaniPres.
  • Charles F. WagnerCFO
  • Michael J. PariniExec.VP
  • David AltshulerExec.VP

Address

Insider Trading

During the most recent quarter, 15K shares were bought, and 95K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.